FOR ONCOLOGISTS
Evidence to inform the next treatment conversation.
PARIS® adds functional drug response information from live tumor cells to the molecular and clinical information already available to you—providing another source of personalized insight as you evaluate potential treatment options with your patient.
WHEN TO CONSIDER PARIS
When more information matters.
PARIS® may be considered when additional personalized information could help inform the treatment conversation, particularly for patients facing complex treatment decisions.
Recurrent or Progressive Cancer
When cancer has returned or progressed following previous treatment.
Rare Cancers
When established treatment pathways or available evidence may be limited.
Limited Standard Options
When standard treatment options are limited or have been exhausted.
Treatment Planning
When additional information about an individual cancer’s response to potential therapies may help inform treatment discussions.
FUNCTIONAL PRECISION ONCOLOGY
Complement genomic insight with functional drug response.
Genomic profiling can identify molecular alterations that may help inform treatment decisions. Functional testing provides a different source of information by directly measuring how living tumor cells respond when exposed to potential therapies.
PARIS® brings these two sources of information together, providing molecular and functional insights that can be considered alongside the patient’s clinical history and other relevant information.
EXPLORE THE METHODOLOGY >
CLINICAL EVIDENCE
Explore the evidence.
Review peer-reviewed publications, clinical studies, case reports and other scientific evidence related to PARIS® and functional precision oncology.
Publications
Explore peer-reviewed research related to PARIS® and the scientific foundation of functional precision oncology.
Case Reports
Review published reports describing functional precision oncology in individual clinical contexts.
Studies
Explore clinical and translational research evaluating functional approaches to precision oncology.
CLIA
PARIS® is available for clinical use through a CLIA-certified laboratory.
FROM TEST TO REPORT
Designed for clinical workflow.
The Cure First team works with physicians and care teams to coordinate PARIS® testing from patient selection through delivery of the report.
1
Identify Patient
Identify a patient for whom additional functional information may be appropriate.
2
Coordinate Sample
Work with Cure First to confirm requirements and coordinate collection and shipment of a fresh tumor sample.
3
Testing
Living tumor cells are prepared and tested against multiple therapies, with functional response evaluated alongside molecular information.
4
Receive Report
The treating physician receives the report with results from the testing performed.
5
Discuss Options
Review the results alongside other clinical information as you and your patient discuss potential treatment options.
DISCUSS A PATIENT
Have a patient in mind?
The Cure First team can help answer questions about patient eligibility, sample requirements, testing coordination and the PARIS® ordering process.